INHIBRX BIOSCIENCES, INC. Proceeds from Issuance of Private Placement
INHIBRX BIOSCIENCES, INC. (INBX) reported Proceeds from Issuance of Private Placement of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2025-03-17
- INHIBRX BIOSCIENCES, INC. proceeds from issuance of private placement for the quarter ending 2024-12-31 was $0.00.
- INHIBRX BIOSCIENCES, INC. proceeds from issuance of private placement for the quarter ending 2023-12-31 was $0.00.
- INHIBRX BIOSCIENCES, INC. proceeds from issuance of private placement for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. proceeds from issuance of private placement for fiscal 2023 was $200.00M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 10-K · filed 2025-03-17 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $200.00M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $200.00M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |